595 related articles for article (PubMed ID: 17001471)
1. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
Raz I; Hanefeld M; Xu L; Caria C; Williams-Herman D; Khatami H;
Diabetologia; 2006 Nov; 49(11):2564-71. PubMed ID: 17001471
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
5. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
Aschner P; Kipnes MS; Lunceford JK; Sanchez M; Mickel C; Williams-Herman DE;
Diabetes Care; 2006 Dec; 29(12):2632-7. PubMed ID: 17130196
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin.
Lyseng-Williamson KA
Drugs; 2007; 67(4):587-97. PubMed ID: 17352516
[TBL] [Abstract][Full Text] [Related]
7. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
Scott R; Wu M; Sanchez M; Stein P
Int J Clin Pract; 2007 Jan; 61(1):171-80. PubMed ID: 17156104
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
Deacon CF
Expert Opin Investig Drugs; 2007 Apr; 16(4):533-45. PubMed ID: 17371200
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
Mohan V; Yang W; Son HY; Xu L; Noble L; Langdon RB; Amatruda JM; Stein PP; Kaufman KD
Diabetes Res Clin Pract; 2009 Jan; 83(1):106-16. PubMed ID: 19097665
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
Dhillon S
Drugs; 2010 Mar; 70(4):489-512. PubMed ID: 20205490
[TBL] [Abstract][Full Text] [Related]
15. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Hanefeld M; Herman GA; Wu M; Mickel C; Sanchez M; Stein PP;
Curr Med Res Opin; 2007 Jun; 23(6):1329-39. PubMed ID: 17559733
[TBL] [Abstract][Full Text] [Related]
16. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.
Nonaka K; Kakikawa T; Sato A; Okuyama K; Fujimoto G; Kato N; Suzuki H; Hirayama Y; Ahmed T; Davies MJ; Stein PP
Diabetes Res Clin Pract; 2008 Feb; 79(2):291-8. PubMed ID: 17933414
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E
Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Scott R; Loeys T; Davies MJ; Engel SS;
Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Signorovitch JE; Wu EQ; Swallow E; Kantor E; Fan L; Gruenberger JB
Clin Drug Investig; 2011; 31(9):665-74. PubMed ID: 21819162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
